In a phase I/II trial led by our group, NK cells engineered to express a CD19-directed CAR molecule together with IL-15 demonstrated remarkable responses in heavily pre-treated patients with CD19 positive hematologic malignancies (16, 31). Here, CD19 is linked to hematologic disorder.